— Know what they know.
Not Investment Advice

MRUS NASDAQ

Merus N.V.
1W: -7.1% 1M: -6.2% 3M: -4.4% 1Y: +113.9% 3Y: +513.5% 5Y: +390.2%
$90.00
Last traded 2025-12-31 — delisted
NASDAQ · Healthcare · Biotechnology · $6.8B mcap · 70M float · 2.45% daily turnover · Short 55% of daily vol

Revenue Segmentation

By Product / Service

Revenue by Segment (5-Year Trend)

Income Trends

Revenue
$35M -12.4% ▼
5Y CAGR: +4.7%
Gross Profit
$13M -55.8% ▼
Operating Income
-$263M -85.2% ▼
Net Income
-$208M -48.1% ▼
EPS (Diluted)
$-3.35 -11.7% ▼
EBITDA
-$260M -86.6% ▼

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
Revenue$25M$43M$39M$40M$35M
YoY Growth-11.7%+76.0%-10.0%+2.5%-12.4%
Cost of Revenue$57M$86M$10M$11M$22M
Gross Profit-$33M-$43M$29M$29M$13M
Gross Margin-133.9%-99.9%74.4%73.6%37.2%
R&D Expenses$62M$94M$148M$133M$230M
SG&A Expenses$29M$36M$49M$54M$80M
Operating Expenses$29M$36M$178M$171M$276M
Operating Income-$62M-$79M-$149M-$142M-$263M
Operating Margin-253.4%-183.2%-384.8%-356.2%-753.0%
Interest Expense$0$129K$0$0$0
Income Before Tax-$70M-$58M-$122M-$137M-$200M
Tax Expense$412K$210K$896K$3M$8M
Net Income-$70M-$59M-$123M-$140M-$208M
Net Margin-285.6%-136.1%-315.5%-352.6%-595.9%
EPS (Diluted)$-2.92$-1.73$-2.92$-3.00$-3.35
EBITDA-$61M-$78M-$148M-$139M-$260M
Shares Outstanding29M39M45M52M64M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms